T-2022

The scenery and atmosphere were wonderful and set the background to an efficient learning experience.

Contents such as EMA DDI guideline and ICH M12; informing of dosing discussion using mechanistic modelling were extremely useful; also glimpse into specific DDI such as contraceptives; use of PBPK modelling to support DDI assessment, food interactions; specific case report … Read More

Important aspects of the meeting were socializing and networking with colleagues from the field of clinical pharmacology, DMPB, modelling and others, and receiving insight from regulatory agents/professionals with regulatory experience and the regulatory panel!

My favourite contents included the ICH guideline presentation and all discussions of the presentations. It was great to have Chinese representatives in. I hope this can be done also in the future. There is a need to connect.

I’ve enjoyed the personal interaction with attendance and discussions, experience with colleagues! Super! Also, discussions with authorities and other attendees was very helpful; I know it (the Workshop) is happening every year for many years, but never made it, so … Read More

Most valuable were insights into Chinese regulatory authorities; update on ICH-M12 roadmap – very beneficial that this harmonization will be finalized soon.

For me from academia the combination of the content was quite good as it gives a good overview over the field.

Highlights of the Workshop were meeting again the community after such a long Covid 19 time; In general, high quality presentations and speakers; big thank to the faculty and the organizers. Great work!

I’ve enjoyed attenting and listening to discussion of such different stake holders (Industry, regulatory, academia).